
Viatris Inc. announced that Theodora Mistras, it's Chief Financial Officer, will leave the company to pursue a new professional opportunity.
Viatris Inc. has appointed Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective 8 May 2026, while it searches for a permanent replacement. Theodora Mistras will remain until May 22, 2026 to support a smooth transition.
Paul Campbell has over 20 years of experience in accounting, finance, and corporate leadership. In his current role at Viatris Inc., he manages global accounting, and finance operations, having been with the company since joining its legacy business Mylan in 2002, where he has helped improve financial processes, support key initiatives and maintain strong financial discipline.
Before his current role, Paul Campbell served as Chief Accounting Officer, Senior Vice President and Controller at Mylan, where he led accounting, financial operations, and reporting and over time held key roles in internal audit, business development, corporate development, and operations finance, supporting the company’s growth, while earlier in his career he spent nearly 10 years at Deloitte & Touche as a Senior Manager in Audit and earned a Bachelor of Science in Accounting from Pennsylvania State University.
Read More:General Proximity Receives Investment from FreeMind Group
"We thank Doretta for her significant contributions, which have helped prepare the Company to enter a period of sustainable future growth," said Scott A. Smith, CEO, Viatris. "Given Paul's deep knowledge of Viatris and his financial expertise and experience, we are confident he is the right transitional leader to maintain continuity and operational discipline while we focus on positioning the Company for sustained long-term growth."
About Viatris
Viatris Inc. is a global healthcare company focused on helping people live healthier lives at every stage by providing access to medicines worldwide including generics, established brands and innovative treatments while ensuring a reliable supply and driving innovation. It is headquartered in the US with major centers in Pittsburgh, Shanghai and Hyderabad.
Read More:Panthalassa Raises $140 Million to Power AI at Sea









